NTV Asset Management LLC reduced its position in GlaxoSmithKline PLC (NYSE:GSK) by 15.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,087 shares of the pharmaceutical company’s stock after selling 4,700 shares during the period. NTV Asset Management LLC’s holdings in GlaxoSmithKline PLC were worth $1,059,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Proficio Capital Partners LLC lifted its stake in shares of GlaxoSmithKline PLC by 16.1% in the 2nd quarter. Proficio Capital Partners LLC now owns 3,301 shares of the pharmaceutical company’s stock valued at $135,000 after purchasing an additional 457 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its stake in shares of GlaxoSmithKline PLC by 1.9% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock valued at $137,000 after purchasing an additional 64 shares during the period. FTB Advisors Inc. lifted its stake in shares of GlaxoSmithKline PLC by 16.9% in the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock valued at $146,000 after purchasing an additional 539 shares during the period. Quadrant Capital Group LLC lifted its stake in shares of GlaxoSmithKline PLC by 3.5% in the 2nd quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after purchasing an additional 148 shares during the period. Finally, Parallel Advisors LLC lifted its stake in shares of GlaxoSmithKline PLC by 93.4% in the 2nd quarter. Parallel Advisors LLC now owns 4,048 shares of the pharmaceutical company’s stock valued at $164,000 after purchasing an additional 1,955 shares during the period. Hedge funds and other institutional investors own 9.32% of the company’s stock.

GSK has been the subject of several analyst reports. TheStreet upgraded shares of GlaxoSmithKline PLC from a “c+” rating to a “b” rating in a research note on Wednesday, October 25th. Argus reiterated a “buy” rating and issued a $50.00 target price on shares of GlaxoSmithKline PLC in a research note on Thursday, August 31st. Zacks Investment Research upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Wednesday, October 18th. Investec cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Monday, November 6th. Finally, J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, October 18th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and five have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $44.33.

COPYRIGHT VIOLATION NOTICE: “NTV Asset Management LLC Has $1.06 Million Position in GlaxoSmithKline PLC (GSK)” was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://theolympiareport.com/2017/11/14/ntv-asset-management-llc-has-1-06-million-position-in-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline PLC (NYSE GSK) traded down $0.20 during trading on Tuesday, hitting $34.89. 2,002,577 shares of the stock were exchanged, compared to its average volume of 3,432,454. GlaxoSmithKline PLC has a fifty-two week low of $34.97 and a fifty-two week high of $44.53. The stock has a market capitalization of $86,814.73, a price-to-earnings ratio of 12.52, a price-to-earnings-growth ratio of 1.96 and a beta of 1.00. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be issued a dividend of $0.5037 per share. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. The ex-dividend date is Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.77%. GlaxoSmithKline PLC’s dividend payout ratio is presently 163.12%.

In other GlaxoSmithKline PLC news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the company’s stock in a transaction dated Monday, November 6th. The stock was acquired at an average price of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 10.00% of the stock is owned by corporate insiders.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.